A selective NLRP3 inflammasome inhibitor MCC950 (a sulfonylurea derivative) attenuates behavioral deficits and neuroinflammation in MPTP-induced mouse model of PD (Huang S. et al., 2021). This evidence concerns the gene NLRP3 and Parkinson disease.